Last reviewed · How we verify
NCT06936007
Hematological Manifestations in Systemic Lupus Erythematosus Patients
trial in Systemic Lupus Erythematosus (SLE) in 99 participants. Completed in 30 December 2024.
30 December 2024
Quick facts
| Lead sponsor | Patan Academy of Health Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 99 |
| Start date | 1 November 2024 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across Nepal |
Conditions studied
- Systemic Lupus Erythematosus (SLE) — all drugs for Systemic Lupus Erythematosus (SLE) →
Sponsor
Patan Academy of Health Sciences
Who can join
Eligibility, any sex, with Systemic Lupus Erythematosus (SLE). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate hematological abnormalities among patients with systemic lupus erythematosus (SLE) admitted to a tertiary care center in Nepal. The main question it aims to answer is: \- What are the types and frequencies of hematological abnormalities seen in hospitalized SLE patients in Nepal? The study retrospectively reviews medical records of SLE patients admitted between April 2018 and March 2023 to collect data on hematologic parameters, demographic profiles, clinical manifestations.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hematological manifestations in systemic lupus erythematosus: a retrospective cross-sectional study from a tertiary care center in Nepal.
Adhikari K, Karki H, Shrestha P, Sigdel KR, et al · · 2025 · PMID 41181399 · DOI 10.1097/ms9.0000000000003765
Verify or expand the search:
- PubMed search for NCT06936007
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erythematosus (SLE)
Currently open trials in the same condition.
- NCT07447986 — To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus · Phase 2 · recruiting
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
- NCT06875960 — A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis · Phase 4 · recruiting
Other Patan Academy of Health Sciences trials
Trials by the same sponsor.
- NCT07004751 — Etiology of Febrile Illness in Nepal (DEFINe Study) · NA · recruiting
- NCT06327867 — Comparison of Video Laryngoscopy Versus Direct Laryngoscopy for Orotracheal Intubation Among Adults in Emergency Departm · NA · not yet recruiting
- NCT03630380 — Accuracy of Clinical and Diagnostic Studies for Pneumonia in Children · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06936007 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Patan Academy of Health Sciences
- Last refreshed: 20 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936007.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing